ESR1 and breast neoplasm: Although such mutations have not been detected in primary breast tumors, Fuqua et al. have detailed on the occurrence of an ERα variant with an A-to-G bp transition, which introduces a Lysine-to-Arginine substitution at residue 303 in almost a third of hyperplastic breast lesions (96).